Skandinaviska Enskilda Banken AB publ Sells 100 Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Skandinaviska Enskilda Banken AB publ cut its holdings in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 2.6% during the fourth quarter, Holdings Channel reports. The fund owned 3,731 shares of the medical research company’s stock after selling 100 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Bio-Rad Laboratories were worth $1,218,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Metis Global Partners LLC grew its holdings in shares of Bio-Rad Laboratories by 4.4% during the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after purchasing an additional 30 shares during the last quarter. Avior Wealth Management LLC lifted its position in Bio-Rad Laboratories by 3.3% during the 3rd quarter. Avior Wealth Management LLC now owns 999 shares of the medical research company’s stock worth $334,000 after buying an additional 32 shares in the last quarter. UMB Bank n.a. increased its position in Bio-Rad Laboratories by 41.6% in the 4th quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares in the last quarter. Tokio Marine Asset Management Co. Ltd. raised its stake in shares of Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after acquiring an additional 34 shares during the last quarter. Finally, CIBC Asset Management Inc raised its stake in shares of Bio-Rad Laboratories by 5.0% in the fourth quarter. CIBC Asset Management Inc now owns 713 shares of the medical research company’s stock worth $234,000 after acquiring an additional 34 shares during the last quarter. 65.24% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

BIO has been the subject of a number of research reports. Royal Bank of Canada reissued an “outperform” rating and issued a $481.00 price target on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. StockNews.com cut Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, February 17th. Finally, Wells Fargo & Company cut their price target on Bio-Rad Laboratories from $360.00 to $345.00 and set an “equal weight” rating on the stock in a research note on Wednesday, February 12th. Three analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $395.20.

Bio-Rad Laboratories Price Performance

BIO opened at $256.35 on Tuesday. The company has a fifty day moving average price of $310.23 and a two-hundred day moving average price of $327.46. The firm has a market capitalization of $7.18 billion, a PE ratio of -3.94 and a beta of 0.98. Bio-Rad Laboratories, Inc. has a 52 week low of $244.00 and a 52 week high of $387.99. The company has a debt-to-equity ratio of 0.18, a quick ratio of 4.85 and a current ratio of 6.48.

Bio-Rad Laboratories (NYSE:BIO) last announced its quarterly earnings data on Thursday, February 13th. The medical research company reported $2.90 EPS for the quarter, topping analysts’ consensus estimates of $2.86 by $0.04. Bio-Rad Laboratories had a positive return on equity of 3.90% and a negative net margin of 71.86%. As a group, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.